Case filing & court posture: Gamida Cell Inc., the U.S. subsidiary of Israeli parent Gamida Cell Ltd., filed a prepackaged chapter 11 on May 13, 2024 in the District of Delaware before Judge J. Kate Stickles. Dkt. 1 Gamida Cell is a biotech company commercializing Omisirge (omidubicel), a cell therapy for allogeneic stem cell transplant in blood cancer patients, with 36 U.S. employees. Dkt. 3
Financial context & restructuring rationale: The company carried $75 million in convertible senior notes and approximately $4.4 million in secured notes, with only $1.78 million in first-time revenue recorded in 2023. Dkt. 3 The restructuring was designed to prevent liquidation, deleverage the company, and secure up to $45 million in new exit financing from Highbridge to fund Omisirge commercialization. Dkt. 3
Prepackaged plan & confirmation: The debtor filed a prepackaged plan of reorganization on the petition date, Dkt. 4 which was confirmed on May 22, 2024 — nine days after filing — with unanimous acceptance from all voting creditor classes.
